Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Esperion Therapeutics, Inc. < Previous 1 2 Next > Esperion Announces Proposed Public Offering of Common Stock January 18, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation January 03, 2024 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference December 18, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet December 13, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023 November 13, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023 November 11, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) November 09, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Reports Third Quarter 2023 Financial Results November 07, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Participate in Jefferies London Healthcare Conference October 31, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Report Third Quarter 2023 Financial Results on November 7 October 24, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference August 28, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023 August 26, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023 August 11, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) August 08, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Reports Second Quarter 2023 Financial Results August 01, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Participate in BTIG Virtual Biotechnology Conference 2023 July 24, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Report Second Quarter 2023 Financial Results on August 1 July 17, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Present Additional Data from the CLEAR Outcomes Study on CVD Prevention at the American Society for Preventive Cardiology (ASPC) Congress 2023 July 07, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet June 28, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Presents Results from CLEAR Outcomes Primary Prevention Analysis at 83rd American Diabetes Association Scientific Sessions June 24, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment at ENDO 2023 June 15, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023 June 08, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023 June 05, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet June 01, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders May 25, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Participate in Jefferies Healthcare Conference May 24, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) May 12, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Reports First Quarter 2023 Financial Results May 09, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9 May 04, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR Esperion to Participate in JMP Securities Life Sciences Conference May 01, 2023 From Esperion Therapeutics, Inc. Via GlobeNewswire Tickers ESPR < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.